Institutional shares held 3.78 Million
0 calls
0 puts
Total value of holdings $567K
$0 calls
$0 puts
Market Cap $5.62M
37,445,900 Shares Out.
Institutional ownership 10.11%
# of Institutions 31


Latest Institutional Activity in RNLX

Top Purchases

Q3 2024
Pinnacle Associates LTD Shares Held: 847K ($127K)
Q3 2024
Baader Bank Aktiengesellschaft Shares Held: 15K ($2.26K)
Q3 2024
Cambridge Investment Research Advisors, Inc. Shares Held: 14.5K ($2.18K)
Q3 2024
Traynor Capital Management, Inc. Shares Held: 61.8K ($9.26K)
Q3 2024
Concourse Financial Group Securities, Inc. Shares Held: 0 ($0)

Top Sells

Q2 2024
Lazard Asset Management LLC Shares Held: 681 ($102)
Q2 2024
Jpmorgan Chase & CO Shares Held: 16.2K ($2.42K)
Q2 2024
Ewa, LLC Shares Held: 16.5K ($2.47K)
Q2 2024
Virtu Financial LLC Shares Held: 12.5K ($1.87K)
Q2 2024
Group One Trading, L.P. Shares Held: 174 ($26.1)

About RNLX

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.


Insider Transactions at RNLX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
9.36M Shares
From 1 Insiders
Other acquisition or disposition 9.36M shares
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on RNLX

Follow Renalytix plc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RNLX shares.

Notify only if

Insider Trading

Get notified when an Renalytix PLC insider buys or sells RNLX shares.

Notify only if

News

Receive news related to Renalytix plc

Track Activities on RNLX